Inovio Pharmaceuticals Faces Class Action: Important Deadline for Investors Approaching

Inovio Pharmaceuticals Class Action Overview

As the deadline approaches for investors of Inovio Pharmaceuticals, Inc. (NASDAQ: INO), critical updates have emerged regarding potential class action lawsuits against the company. Investors who acquired securities between October 10, 2023, and December 26, 2025, are encouraged to review their legal options as Faruqi & Faruqi, LLP, a prominent national securities law firm, is actively pursuing claims against Inovio Pharmaceuticals.

The Allegations Against Inovio

The complaint alleges that Inovio and its executives breached federal securities laws by issuing false or misleading statements about the company's operations and prospects. Key points of concern include:
1. Deficiencies in Manufacturing: It has been claimed that manufacturing processes related to Inovio's CELLECTRA device were inadequate.
2. Delayed BLA Submission: Investors were led to believe that the Biologics License Application (BLA) for the INO-3107 treatment would be submitted to the FDA in the latter half of 2024. This timeline is now in question due to claims of insufficient information to validate its eligibility for FDA's accelerated approval.
3. Overstated Prospects: The company's public statements regarding INO-3107's regulatory and commercial prospects have reportedly been exaggerated, misleading investors on the viability of the treatment.

These accusations led to a significant drop in Inovio's stock price. After announcements concerning the BLA submission status on December 29, 2025, the stock plummeted by approximately 24.45%, closing at $1.73.

Seeking Lead Plaintiff Status

Investors who wish to participate in the class-action suit may apply for lead plaintiff status. The lead plaintiff is typically the member of the class with the largest financial stake in the case, who takes on a leadership role in overseeing the lawsuit on behalf of other class members. Individuals looking to join the action can either seek legal counsel or remain as absent class members. Importantly, participation status will not affect the potential recovery of any settlements reached in the case.

How to Get Involved

For those affected by the alleged misconduct, Faruqi & Faruqi encourages you to act promptly. Investors can reach out directly to James (Josh) Wilson, a partner at the firm, at 877-247-4292 or 212-983-9330 (Ext. 1310). The firm's website also provides ongoing updates about the case and serves as a useful resource for up-to-date information regarding Inovio's situation.

Conclusion

With the April 7, 2026, deadline approaching, investors are reminded to assess their positions carefully. This is a pivotal moment for stakeholders in Inovio Pharmaceuticals as the outcome of the class action could influence both the financial future of the company and the potential recourse available to affected investors. As the situation develops, keeping informed and ready to take action will be crucial for those invested in Inovio Pharmaceuticals.

To learn more specifics about the class action, interested parties can visit the Faruqi & Faruqi website for detailed information. This case highlights the necessity of due diligence and the importance of investors' rights in the face of corporate misrepresentation.